Teprotumumab-Related Hyperglycemia
Authors' conclusion
While effective, teprotumumab carries a significant risk of hyperglycemia, especially in patients with diabetes. Hyperglycemia may persist after stopping teprotumumab. These findings underscore the importance of guidelines for screening and management of teprotumumab-related hyperglycemia.
Study context
- Population
- All consecutive patients with Graves orbitopathy treated with teprotumumab, March 2020–May 2022, 1 academic institutionmean follow-up 47.5 weeks
- Participants
- 42 patients
- Exposure
- Normoglycemia vs Prediabetes vs Diabetes
- Normoglycemian = 22
- Prediabetesn = 10
- Diabetesn = 10
- Outcome
- Incidence, severity, management and longitudinal glycemic changes (HbA1c every 3 months)
Methodological detailssingle-institution, consecutive patients, Hemoglobin A1c (HbA1c) measured every 3 months
- Single-institution
- Consecutive patients
- HbA1c measured every 3 months
Main finding
As reported in the abstract
3 months (HbA1c)
| Group | Value | P |
|---|---|---|
| Diabetes | least-squares mean change 1.3 | P < .001 |
| Prediabetes | least-squares mean change 0.7 | P = .01 |
| Normoglycemia | least-squares mean change 0.1 | P = .41 |
Value
Diabetesleast-squares mean change 1.3
Prediabetesleast-squares mean change 0.7
Normoglycemialeast-squares mean change 0.1
P
DiabetesP < .001
PrediabetesP = .01
NormoglycemiaP = .41
- Overall HbA1c increase at 3 months
- 0.5%
- Hyperglycemia
- 22 patients (52%)
- Graded mild
- 55% (12/22)
- Graded moderate
- 41% (9/22)
- Graded life-threatening
- 5% (1/22)
Observational data: associations, not effects.
Further findings
Risk factors for hyperglycemia
- Age, pre-existing diabetes, and Hispanic and Asian race/ethnicity were significant risk factors
Return to baseline glycemic status among patients with hyperglycemia · last follow-up
- Returned to baseline glycemic status
- 36.4% (8/22)
Safety
- Hyperglycemia
- 22 patients (52%)
- Life-threatening hyperglycemia
- 5% (1/22)
Original publication
Teprotumumab-Related Hyperglycemia. J Clin Endocrinol Metab. Published 27 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →